Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
126 studies found for:    GLP-1R
Show Display Options
Rank Status Study
1 Unknown  DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists
Condition: Diabetes
Intervention: Drug: Exenatide, Liraglutide
2 Completed Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Conditions: Obesity;   Diabetes
Interventions: Drug: BYETTA treatment;   Drug: Metformine
3 Completed
Has Results
GLP1R Polymorphisms and Response to GLP1
Condition: Diabetes
Intervention: Drug: GLP-1
4 Recruiting The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Liraglutide;   Drug: metformin
5 Terminated TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy
Condition: Diabetes Mellitus, Type 2
Intervention: Device: TANTALUS System
6 Recruiting Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain
Condition: Diabetes Mellitus
Interventions: Drug: Lixisenatide;   Other: Placebo
7 Completed Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Ipragliflozin
8 Unknown  Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status
Condition: Obesity
Intervention: Drug: Exenatide
9 Recruiting Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide;   Drug: placebo
10 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
11 Completed The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Other: Training and liraglutide;   Other: Training and placebo
12 Recruiting Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
13 Completed SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
Condition: Type 2 Diabetes
Interventions: Drug: Liraglutide;   Drug: Sitagliptin;   Drug: Exenatide;   Drug: Liraglutide placebo;   Drug: Sitagliptin placebo;   Drug: Exenatide placebo;   Drug: L-NMMA
14 Completed The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide;   Drug: liraglutide;   Drug: exenatide
15 Not yet recruiting Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Dapagliflozin;   Drug: Exenatide;   Drug: Placebo
16 Completed The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
Conditions: Diabetes Mellitus;   Diabetes Mellitus, Type 2;   Obesity
Interventions: Drug: exenatide;   Drug: exenatide + exendin (9-39);   Drug: placebo
17 Not yet recruiting Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
Conditions: Obesity;   Type 2 Diabetes Mellitus
Intervention: Drug: Liraglutide 3.0 mg
18 Active, not recruiting Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
Condition: Impaired Glucose Tolerance Associated With Drugs
Interventions: Drug: Liraglutide;   Drug: Liraglutide Placebo
19 Completed
Has Results
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Oxyntomodulin;   Drug: Liraglutide 0.6 mg;   Drug: Liraglutide 1.2 mg;   Drug: Placebo for Oxyntomodulin;   Drug: Placebo for Liraglutide
20 Completed PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes
Condition: Diabetes
Intervention: Drug: second- or third-line glucose-lowering diabetes treatment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.